Tumor‐Selective Activation of Toll‐Like Receptor 7/8 Agonist Nano‐Immunomodulator Generates Safe Anti‐Tumor Immune Responses upon Systemic Administration-Reference-Cited by-同舟云学术

Tumor‐Selective Activation of Toll‐Like Receptor 7/8 Agonist Nano‐Immunomodulator Generates Safe Anti‐Tumor Immune Responses upon Systemic Administration

Published:2022-11-24 Issue:52 Volume:61 Page:
ISSN:1433-7851
Container-title:Angewandte Chemie International Edition
language:en
Short-container-title:Angew Chem Int Ed

Author:

Hao Yanyun¹,Li Hui¹,Ge Xiaoyan¹,Liu Yang¹,Li Xia¹,Liu Yutong¹,Chen Hongfei¹,Zhang Shiying¹,Zou Jing¹,Huang Lingling¹,Zhao Fabao²,Kang Dongwei²,De Geest Bruno G.³,Zhang Zhiyue¹^ORCID

Affiliation:

1. NMPA Key Laboratory for Technology Research and Evaluation of Drug Products Key Laboratory of Chemical Biology (Ministry of Education) Department of Pharmaceutics School of Pharmaceutical Sciences, Cheeloo College of Medicine Shandong University Jinan Shandong, 250012 China

2. Department of Medicinal Chemistry Key Laboratory of Chemical Biology (Ministry of Education) School of Pharmaceutical Sciences Cheeloo College of Medicine Shandong University Jinan Shandong, 250012 China

3. Department of Pharmaceutics Ghent University Ottergemsesteenweg 460 9000 Ghent Belgium

Funder

Natural Science Foundation of Shandong Province

National Natural Science Foundation of China

Publisher

Wiley

Subject

General Chemistry,Catalysis

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/anie.202214992

Reference33 articles.

1. Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells